Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: Preliminary results

Investigative Radiology

Volumn 41, Issue 1, 2006, Pages 15-21

  Bertolotto, Michele ^a   Pozzato, Gabriele ^a   Crocè, Lory Saveria ^a   Nascimben, Fabiana ^b   Gasparini, Cristiana ^a   Cova, Maria Assunta ^a   Tiribelli, Claudio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Blood; Flow dynamics; Hepatocellular carcinoma (HCC); Microbubble contrast agents; Perfusion; Quantification; Thalidomide treatment; Tumor; Ultrasound (US); US contrast agents

Indexed keywords

CONTRAST MEDIUM; SONOVUE; THALIDOMIDE; ANGIOGENESIS INHIBITOR; CONTRAST AGENT BR1; DIAGNOSTIC AGENT; PHOSPHOLIPID; SULFUR HEXAFLUORIDE;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG EFFECT; FEMALE; FLOW KINETICS; HUMAN; LIVER BLOOD FLOW; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; LIVER PERFUSION; MALE; MICROBUBBLE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; ULTRASOUND; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; IMAGE PROCESSING; LIVER CELL CARCINOMA; LIVER TUMOR; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; SURVIVAL; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER NEOPLASMS; MALE; MICROBUBBLES; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPIDS; STATISTICS, NONPARAMETRIC; SULFUR HEXAFLUORIDE; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33645057729     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000188363.93670.45     Document Type: Article

References (35)

1. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720-727.
2. Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol. 1998;29:650-659.
3. Zhang ZL, Liu ZS, Sun Q. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J Gastroenterol. 2005;11:216-220.
4. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
5. Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 1998;236:461-466.
6. Patt YZ, Hassan MM, Lozano RD, et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol. 2000;23:319-321.
7. Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology. 2003;65:242-249.
8. Hsu C, Chen CN, Chen LT, et al. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. Radiology. 2005;235:509-516.
9. Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer. 2005;103:119-125.
10. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005;103:749-755.
11. Wadler S. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative? Cancer. 2005;103:1-4.
12. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998;97:473-483.
13. Meairs S, Daffertshofer M, Neff W, et al. Pulse-inversion contrast harmonic imaging: ultrasonographic assessment of cerebral perfusion. Lancet. 2000;355:550-551.
14. Seidel G, Claassen L, Meyer K, et al. Evaluation of blood flow in the cerebral microcirculation: analysis of the refill kinetics during ultrasound contrast agent infusion. Ultrasound Med Biol. 2001;27:1059-1064.
15. Wei K, Le E, Bin JP, et al. Quantification of renal blood flow with contrast-enhanced ultrasound. J Am Coll Cardiol. 2001;37:1135-1140.
16. Chomas JE, Pollard RE, Sadlowski AR, et al. Contrast-enhanced US of microcirculation of superficially implanted tumors in rats. Radiology. 2003;229:439-446.
17. Broumas AR, Pollard RE, Bloch SH, et al. Contrast-enhanced computed tomography and ultrasound for evaluation of tumor blood flow. Invest Radiol. 2005;40:134-147.
18. Lucidarme O, Franchi-Abella S, Correas JM, et al. Blood flow quantification with contrast-enhanced US: "entrance in the section" phenomenon-phantom and rabbit study. Radiology. 2003;228:473-479.
19. Gasparini C, Bertolotto M, Croce SL, et al. Evaluation of liver parenchymal blood flow with contrast-enhanced US: preliminary results in healthy and cirrhotic patients. Acad Radiol. 2003;10:869-876.
20. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the tratment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
21. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-160.
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
23. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
24. Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16:1-6.
25. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302-306.
26. Stebbing J, Benson C, Eisen T, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer. 2001;85:953-958.
27. Wang J, Chen LT, Tsang YM, et al. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol. 2004;183:713-719.
28. Mayr NA, Hawighorst H, Yuh WT, et al. MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome. J Magn Reson Imaging. 1999;10:267-276.
29. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol. 2000;34:148-155.
30. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol. 2001;56:607-620.
31. Pollard RE, Garcia TC, Stieger SM, et al. Quantitative evaluation of perfusion and permeability of peripheral tumors using contrast-enhanced computed tomography. Invest Radiol. 2004;39:340-349.
32. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol. 1999;30:198-205.
33. Krix M, Kiessling F, Vosseler S, et al. Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals. Ultrasound Med Biol. 2003;29:1093-1103.
34. Morel DR, Schwieger I, Hohn L, et al. Human pharmacokinetics and safety evaluation of SonoVue™, a new contrast agent for ultrasound imaging. Invest Radiol. 2000;35:80-85.
35. Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004;232:420-430.